ICON Plc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
ICON PLC (ICLR)
The ICON PLC share price today is 116.57, view NASDAQ ICLR stock exchange data. Track the latest ICON PLC share price with real-time updates on ICLR stock performance including market cap, day range, 52-week range and dividend yield. Access ICLR charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
112.43
116.80
52 wk Range
66.57
211.00
Earnings results expected today
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
112.43116.80
52 wk Range
66.57211.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ICLR Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
132.60
Upside
+13.75%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High shareholder yield
- ICON Plc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - ICON Plc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- ICON Plc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - ICON Plc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 13G ICON PLC For: 15 May
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
8 Buy
7 Hold
1 Sell
Ratings:
16 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 132.60
(+13.75% Upside)
ICON PLC SWOT Analysis
CRO Market Dynamics | Explore ICON's navigation of industry challenges, including bookings volatility and demand uncertainties in the competitive CRO landscape |
Financial Resilience | Delve into ICON's solid financial health, with EPS forecasts of $13.40 (FY1) and $14.06 (FY2), despite recent market pressures |
Strategic Positioning | Learn how ICON leverages proprietary technology and global scale to capture high-quality opportunities in a shifting pharmaceutical landscape |
Valuation Insights | Analysts set price targets ranging from $155 to $263, suggesting potential for value realization as transient headwinds subside |
ICON PLC Earnings Call Summary for Q3/2025
- ICON PLC beats Q3 2025 expectations with EPS of $3.31 and revenue of $2.043 billion, up 0.6% year-over-year
- Stock declines despite strong earnings; company maintains 'GREAT' financial health score of 3.18/5
- Focus on AI technologies and biotech market penetration amid regulatory improvements
- Full-year 2025 revenue guidance set at $8.05-$8.1 billion; adjusted EPS expected between $13-$13.20
- Elevated cancellations remain a challenge; normalization anticipated in 2026
Last Updated: 23-10-2025, 07:08 pm
Read Full TranscriptEarnings
Latest Release
30-04-2026
EPS / Forecast
3.20 / 3.31
Revenue / Forecast
2B / 2.01B
Compare ICLR to Peers and Sector
Metrics to compare | ICLR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipICLRPeersSector | |
|---|---|---|---|---|
P/E Ratio | 14.8x | 22.3x | −0.5x | |
PEG Ratio | −0.87 | −1.12 | 0.00 | |
Price/Book | 1.0x | 2.7x | 2.6x | |
Price / LTM Sales | 1.1x | 2.2x | 3.1x | |
Upside (Analyst Target) | 13.0% | 36.1% | 53.0% | |
Fair Value Upside | Unlock | 17.5% | 6.3% | Unlock |
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the ICON PLC (ICLR) Share Price Today?
The ICON PLC share price today is 116.57.
What is the current ICON PLC (ICLR) share price and day range?
As of 22-05-2026, the ICON PLC share price is 116.57, with a previous close of 116.57. The share price has ranged from 112.43 to 116.80 today, while the 52-week range spans from 66.57 to 211.00.
What Is the ICON PLC Market Cap?
As of today, ICON PLC market cap is 8.86B.
What Is the ICON PLC (ICLR) Share Price Target?
The average 12-month share price target for ICON PLC is 132.60, with a high estimate of 180 and a low estimate of 90. 8 analysts recommend buying, while 1 suggest selling, with an overall rating of Buy and +13.75% Upside potential.
What Is ICON PLC's Earnings Per Share (TTM)?
The ICON PLC EPS (TTM) is 7.47.
When Is the Next ICON PLC Earnings Date?
ICON PLC will release its next earnings report on 22-05-2026.
From a Technical Analysis Perspective, Is ICLR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
What Stock Exchange Does ICON PLC Trade On?
ICON PLC is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for ICON PLC?
The stock symbol for ICON PLC is "ICLR."
How Many Times Has ICON PLC Stock Split?
ICON PLC has split 2 times.
How Many Employees Does ICON PLC Have?
ICON PLC has 39800 employees.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.